Cargando…

Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report

Polypharmacy of psychotropic medications predisposes older adults to adverse drug events (ADEs). One contributing factor is inhibition of metabolic pathways between substrates (competitive inhibition) or between substrates and inhibitors of the same cytochrome P450 (CYP450) isoforms. The purpose of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amundson, Collin J., Knight, Robert, Ybarra, Georgina M., Turgeon, Jacques, Bingham, Jennifer M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953614/ https://www.ncbi.nlm.nih.gov/pubmed/35334614 http://dx.doi.org/10.3390/medicina58030438

Ejemplares similares

Mitigating Benzodiazepine Dependence and the Risk of Drug-Induced QTc Prolongation in the Treatment of Gastroparesis: A Case Report
por: Tranchina, Karley, et al.
Publicado: (2022)

Augmentation treatment in major depressive disorder: focus on aripiprazole
por: Nelson, J Craig, et al.
Publicado: (2008)

Clinical correlates of augmentation/combination treatment strategies in major depressive disorder
por: Dold, M., et al.
Publicado: (2018)

Polygenic interactions with environmental adversity in the aetiology of major depressive disorder
por: Mullins, N., et al.
Publicado: (2016)

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
por: Berman, Robert M, et al.
Publicado: (2011)

Childhood adversities are different in Schizophrenic Spectrum Disorders, Bipolar Disorder and Major Depressive Disorder
por: Bruni, Antonella, et al.
Publicado: (2018)

Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review
por: Caldiroli, Alice, et al.
Publicado: (2021)

Effectiveness of an Advanced Clinical Decision Support System on Clinical Decision-Making Skills in a Call Center Medication Therapy Management Pharmacy Setting: A Pilot Study
por: Bingham, Jennifer M., et al.
Publicado: (2020)

Ketamine Augmentation of Electroconvulsive Therapy: A Scoping Review of Dose-Dependent Effects in Major Depressive Disorder
por: Nagi, Tarika, et al.
Publicado: (2023)

Suicide‐specific mortality among patients with treatment‐resistant major depressive disorder, major depressive disorder with prior suicidal ideation or suicide attempts, or major depressive disorder alone
por: Kern, David M., et al.
Publicado: (2023)

Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder
por: Wen, X.J., et al.
Publicado: (2014)

Adverse drug reactions among major depressive disorders: patterns by age and gender
por: Sisay, Tariku, et al.
Publicado: (2021)

Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder
por: Shin, Cheolmin, et al.
Publicado: (2021)

Bridging Basic and Clinical Research in Early Life Adversity, DNA Methylation, and Major Depressive Disorder
por: Brown, Amanda, et al.
Publicado: (2019)

Cultivating COVID-19 Vaccine Confidence in Pharmacy Professionals
por: Aqel, Osama, et al.
Publicado: (2023)

Understanding and mitigating the environmental barriers that patients with major depressive disorder face when transitioning to independent exercise
por: Bandara, Nilanga Aki
Publicado: (2021)

Experimental Therapeutics in Treatment-Resistant Major Depressive Disorder
por: Kaur, Mandeep, et al.
Publicado: (2021)

PS78. Naturalistic, retrospective comparison between antidepressant therapy and atypical antipsychotic augmentation therapy for patients with major depressive disorder
por: Cho, Se Hoon, et al.
Publicado: (2016)

Pharmacist assessment of drug-gene interactions and drug-induced phenoconversion in major depressive disorder: a case report
por: Del Toro-Pagán, N. M., et al.
Publicado: (2022)

Effects of childhood adversity on the volumes of the amygdala subnuclei and hippocampal subfields in individuals with major depressive disorder
por: Aghamohammadi-Sereshki, Arash, et al.
Publicado: (2021)

Childhood Adversity Impairs Theory of Mind Abilities in Adult Patients With Major Depressive Disorder
por: Simon, Maria, et al.
Publicado: (2019)

Executive Subdomains Are Differentially Associated With Psychosocial Outcomes in Major Depressive Disorder
por: Knight, Matthew J., et al.
Publicado: (2018)

Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice
por: Han, Changsu, et al.
Publicado: (2015)

The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study
por: Han, Changsu, et al.
Publicado: (2019)

Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder
por: Rong, Carola, et al.
Publicado: (2018)

Assessment of Glycosylated Hemoglobin Outcomes Following an Enhanced Medication Therapy Management Service via Telehealth
por: Bingham, Jennifer M., et al.
Publicado: (2021)

Proteasome system dysregulation and treatment resistance mechanisms in major depressive disorder
por: Minelli, A, et al.
Publicado: (2015)

Signatures of HIV and Major Depressive Disorder in the Plasma Microbiome
por: Taylor, Bryn C., et al.
Publicado: (2023)

Epidemiology of treatment resistant depression among major depressive disorder patients in Israel
por: Sharman Moser, Sarah, et al.
Publicado: (2022)

Temperament and major depressive disorder
por: Karam, Elie G, et al.
Publicado: (2010)

Assessment of pharmacists' self-reported preparedness to provide pharmacotherapy services to individuals with psychiatric disorders
por: German, Alexander, et al.
Publicado: (2018)

Executive Function and Spatial Cognition Mediate Psychosocial Dysfunction in Major Depressive Disorder
por: Knight, Matthew J., et al.
Publicado: (2018)

Serotonin receptors and suicide, major depression, alcohol use disorder and reported early life adversity
por: Underwood, Mark D., et al.
Publicado: (2018)

Adverse Effects of Esketamine for the Treatment of Major Depression Disorder: Findings from Randomized Controlled Trials
por: Yang, Siyuan, et al.
Publicado: (2021)

Effectiveness and Tolerability of Korean Red Ginseng Augmentation in Major Depressive Disorder Patients with Difficult-to-treat in Routine Practice
por: Lee, Kyung Ho, et al.
Publicado: (2020)

The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder
por: Bartova, Lucie, et al.
Publicado: (2021)

Dextroamphetamine-Amphetamine Augmentation in the Treatment of Treatment-Resistant Depression
por: Small, Tyler M, et al.
Publicado: (2022)

Sex‐related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression
por: Bartova, Lucie, et al.
Publicado: (2021)

Probiotics as an Adjuvant Therapy in Major Depressive Disorder
por: Vlainić, Josipa, et al.
Publicado: (2016)

S-Adenosyl-L-Methionine Augmentation in Patients with Stage II Treatment-Resistant Major Depressive Disorder: An Open Label, Fixed Dose, Single-Blind Study
por: De Berardis, Domenico, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_lq2gr5scj5l5cg7v7662hgl62h